If you've tried antidepressant after antidepressant with little relief, or you're a behavioral health operator watching ketamine programs proliferate and wondering if it's right for your patient population, you're asking the right question: who is a candidate for ketamine infusion therapy?
The answer is more nuanced than the generic "treatment-resistant depression" label you'll find in most articles. Ketamine has moved from experimental to mainstream faster than almost any psychiatric intervention in recent history, but proper patient selection remains the difference between life-changing outcomes and wasted resources or worse, patient harm.
This guide goes deep on the clinical criteria, the conditions with strong evidence, the absolute contraindications, and what the intake process actually looks like at a properly run program. We'll also cover what adding ketamine to a behavioral health program requires from an operational and regulatory standpoint.
What Ketamine Infusion Therapy Actually Is (And Why It Works So Fast)
Ketamine is a noncompetitive NMDA receptor antagonist. That's the technical term. What it means in practice is that ketamine preferentially blocks NMDARs on inhibitory interneurons, leading to disinhibition, increased glutamate release in the prefrontal cortex, reduced eEF2 phosphorylation, enhanced BDNF translation and synaptic potentiation.
The result? Rapid antidepressant effects within hours rather than weeks. This is fundamentally different from traditional SSRIs and SNRIs, which require weeks to months of daily dosing before any therapeutic benefit emerges.
More specifically, ketamine causes disinhibition of pyramidal neurons via preferential effects on GABAergic interneurons, increasing extracellular glutamate and activating mTOR/BDNF pathways for rapid and sustained antidepressant actions. It selectively inhibits NMDARs on GABAergic interneurons, causing glutamate surge and network activation while also blocking resting NMDAR activity to boost BDNF translation.
Why does this matter for candidacy? Because ketamine's rapid onset makes it uniquely suited for specific patient populations: those in acute suicidal crisis, those who've cycled through years of failed antidepressant trials, and those whose depression is so severe that waiting 6-8 weeks for a new SSRI to maybe work isn't clinically acceptable.
The Primary Candidacy Criterion: Treatment-Resistant Depression (TRD)
Most ketamine programs define treatment-resistant depression as the baseline threshold for candidacy. But what does that actually mean?
TRD is typically defined as failure to respond to at least two adequate trials of antidepressant medications. "Adequate" means therapeutic doses for sufficient duration, usually 6-8 weeks at target dose.
So a patient who tried Zoloft for three weeks at 25mg and stopped because they didn't feel better doesn't meet TRD criteria. A patient who completed 8 weeks of sertraline 150mg and 8 weeks of bupropion XL 300mg with minimal response does.
This threshold exists for good reason. Ketamine isn't a first-line treatment. It's Schedule III controlled, requires medical supervision during administration, and carries risks that don't make sense for someone who might respond to conventional therapy. The evidence base and FDA approval for esketamine specifically target TRD populations.
For behavioral health operators evaluating whether to add ketamine services, understanding TRD prevalence in your patient population is critical. If you're running an intensive outpatient program where most clients are early in their treatment journey, ketamine may not be the right fit. If you're serving chronic, complex patients who've been through multiple medication trials, the clinical case is much stronger.
Conditions With Strong Evidence for Ketamine Therapy
Treatment-resistant depression is the most studied indication, but it's not the only one. Here's what the evidence actually shows:
Treatment-Resistant Depression (TRD)
This is the gold standard indication. Multiple randomized controlled trials show that 50-70% of patients with TRD experience significant symptom reduction within 24 hours of a single ketamine infusion. Response rates remain superior to placebo across repeated infusions in the induction phase (typically 6 infusions over 2-3 weeks).
Bipolar Depression
Ketamine shows promise for depressive episodes in bipolar disorder, particularly when traditional mood stabilizers and antidepressants have failed. The rapid onset is especially valuable here, though concerns about triggering mania require careful monitoring and concurrent mood stabilizer therapy.
PTSD
Emerging evidence suggests ketamine can reduce PTSD symptom severity, particularly intrusive thoughts and hyperarousal. The mechanism likely involves disrupting reconsolidation of traumatic memories. This is particularly relevant for behavioral health programs serving veteran populations or trauma-focused treatment tracks.
OCD
Small studies show rapid reduction in obsessive-compulsive symptoms, though effects may be shorter-lived than for depression. Ketamine appears most effective for patients with comorbid depression and OCD rather than OCD alone.
Acute Suicidal Ideation
This may be ketamine's most clinically significant application. The ability to reduce suicidal thoughts within hours makes it invaluable in crisis settings. Some psychiatric emergency departments and inpatient units now use ketamine specifically for patients presenting with active suicidal ideation.
Chronic Neuropathic Pain
Ketamine has a long history in pain management. For patients with comorbid depression and chronic pain (a common combination), ketamine can address both conditions simultaneously. This is especially relevant for programs integrating addiction treatment with chronic pain management.
Who Is NOT a Candidate: Absolute and Relative Contraindications
Proper patient selection means knowing who to exclude. These contraindications exist because ketamine carries real risks in certain populations:
Active Psychosis or Schizophrenia Spectrum Disorders
Ketamine can produce dissociative and perceptual disturbances that may worsen psychotic symptoms. Patients with schizophrenia, schizoaffective disorder, or active psychotic features are generally excluded from ketamine programs.
Uncontrolled Hypertension
Ketamine causes transient increases in blood pressure and heart rate during infusion. Patients with poorly controlled hypertension (typically >140/90 despite medication) require medical optimization before ketamine therapy. This is a relative contraindication that can be addressed with proper cardiovascular management.
Active Substance Use Disorder (Particularly Dissociatives)
This is nuanced. Ketamine has actually shown promise for treating certain substance use disorders, particularly alcohol and cocaine dependence. However, active use of dissociative drugs (ketamine, PCP, DXM) is an absolute contraindication due to abuse potential and tolerance.
For patients in early recovery from other substances, the risk-benefit calculation depends on stability, recovery support, and integration with addiction treatment. Programs offering ketamine therapy as part of addiction treatment integration need clear protocols around sobriety requirements and relapse monitoring.
Certain Cardiovascular Conditions
Unstable angina, recent myocardial infarction, uncontrolled arrhythmias, and severe valvular disease are contraindications. Stable cardiovascular disease with cardiology clearance may be acceptable depending on the specific condition and program protocols.
Pregnancy and Breastfeeding
Ketamine crosses the placenta and is excreted in breast milk. It's contraindicated in pregnancy except in emergency situations. Women of childbearing age typically require pregnancy testing before each infusion.
Severe Hepatic Impairment
Ketamine is metabolized by the liver. Severe hepatic dysfunction can lead to prolonged effects and increased risk of adverse events.
For behavioral health operators, having clear inclusion and exclusion criteria isn't just good clinical practice. It's essential for liability management and regulatory compliance, particularly as credentialing and oversight standards continue to evolve.
IV Ketamine Infusion vs. Esketamine (Spravato) Nasal Spray
When patients and operators research ketamine therapy, they encounter two distinct modalities. Understanding the differences is critical for candidacy determination.
Esketamine (Spravato) Nasal Spray
Esketamine is FDA-approved for treatment-resistant depression in adults after failure of 2+ oral antidepressants. It must be administered in a certified healthcare setting under observation due to REMS (Risk Evaluation and Mitigation Strategy) requirements.
The key advantage: insurance coverage. Because Spravato is FDA-approved, many commercial and Medicare plans cover it (though prior authorization and documentation of failed trials are required). Medicaid coverage varies by state.
The limitations: Spravato is only approved for TRD and depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. It's not approved for PTSD, OCD, bipolar depression, or chronic pain. The nasal spray delivery also produces more variable absorption than IV administration.
IV Ketamine Infusion
This is off-label use of generic ketamine administered intravenously over 40-60 minutes. Dosing is more precise, bioavailability is 100%, and clinicians have more flexibility in protocol design.
The advantage: broader clinical application across the conditions discussed above, more consistent dosing, and often faster onset of therapeutic effects.
The major limitation: almost never covered by insurance. Patients typically pay out of pocket, with costs ranging from $400-800 per infusion. An initial series of 6 infusions can run $2,400-4,800, putting it out of reach for many patients who might benefit.
For operators, the choice between offering Spravato, IV ketamine, or both depends on your patient population's insurance mix, your facility's ability to meet REMS certification requirements, and your medical staffing model.
What the Clinical Intake Process Actually Looks Like
At a well-run ketamine program, candidacy isn't determined by a single criterion. It's a comprehensive evaluation process:
Psychiatric Screening
A thorough psychiatric evaluation by a qualified prescriber (psychiatrist, psychiatric NP, or in some states, other licensed prescribers) documenting diagnosis, treatment history, current symptoms, and specific medication trials with doses and durations. This is where TRD criteria are formally established.
Medical Clearance
Review of medical history, current medications, vital signs, and in many programs, baseline ECG and lab work. Patients with cardiovascular or hepatic concerns may need specialist clearance before proceeding.
Informed Consent
Detailed discussion of what to expect during infusion (dissociative effects, perceptual changes, physical sensations), potential side effects, the lack of FDA approval for off-label IV use, costs, and the importance of integration therapy for sustaining benefits.
Set and Setting
Ketamine's effects are highly influenced by environment and mindset. Good programs create calm, comfortable infusion spaces with options for music, eye masks, and minimal stimulation. They also prepare patients for the dissociative experience rather than letting it come as a surprise.
Integration Therapy
This is where many programs fall short. Ketamine creates a window of neuroplasticity, but lasting change requires therapeutic work during that window. Integration sessions with a therapist who helps patients process insights and implement behavioral changes are essential for sustained benefit.
Follow-Up Protocols
Monitoring for response, managing side effects, determining maintenance infusion frequency, and coordinating with existing psychiatric care. Ketamine shouldn't exist in isolation from a patient's broader treatment plan.
Just as NARR certification establishes quality standards for recovery residences, ketamine programs need clear clinical protocols that ensure patient safety and optimize outcomes.
The Operator Perspective: What Adding Ketamine Requires
For behavioral health treatment centers evaluating whether to add ketamine services, the clinical question is only part of the equation. Here's what implementation actually requires:
DEA Schedule III Compliance
Ketamine is Schedule III controlled. Your facility needs appropriate DEA registration, secure storage, inventory tracking, and disposal protocols. This is more complex than managing Schedule IV benzodiazepines but less restrictive than Schedule II stimulants.
Medical Staffing Models
Who administers the ketamine? Options include:
- Anesthesiologist or CRNA model: highest cost, maximum safety margin, may be overkill for psychiatric dosing
- Psychiatrist or psychiatric NP model: more cost-effective, appropriate for most programs, requires comfort with IV administration and managing dissociative effects
- Collaborative model: prescriber orders, RN administers under supervision
The model you choose affects staffing costs, liability, and the patient populations you can safely serve. Similar considerations apply when planning medical staffing for new treatment programs in regulated environments.
Facility Requirements
Dedicated infusion space with monitoring equipment (pulse oximetry, blood pressure, continuous observation), emergency equipment (oxygen, airway management supplies), recovery area, and appropriate documentation systems. For Spravato, you'll need REMS certification with specific facility and observation protocols.
Liability Considerations
Professional liability insurance that specifically covers ketamine administration (many policies exclude it or require riders), informed consent documentation, protocols for managing adverse events, and clear contraindication screening. Consult with healthcare counsel before launching services.
Integration With Existing Programs
How does ketamine fit with your current service lines? For IOP/PHP programs, ketamine can be an adjunct that helps patients engage more effectively in therapy. For residential programs, it can accelerate response in patients with severe depression or suicidal ideation. For addiction treatment programs, it requires careful integration with recovery principles and relapse prevention.
The operational complexity is similar to adding other specialized services. Just as practices outgrow basic tools and need more robust infrastructure to scale, adding ketamine requires systems that can handle the clinical, regulatory, and billing complexity.
Financial Model
For IV ketamine, you're building a cash-pay service line. Pricing needs to cover staffing, medication, supplies, facility costs, and integration therapy while remaining accessible. For Spravato, you're navigating prior authorization, REMS documentation, and insurance billing complexity.
Many programs find that ketamine services can be financially sustainable while serving patients who truly need them, but it requires realistic financial modeling and operational discipline.
Frequently Asked Questions
Do I need to have tried a specific number of medications to qualify for ketamine therapy?
Most programs require at least two adequate trials of antidepressant medications (meaning therapeutic doses for 6-8 weeks each) with inadequate response. This is the standard definition of treatment-resistant depression. Some programs may have more flexible criteria for patients with acute suicidal ideation or specific conditions like PTSD, but documented prior treatment history is generally required.
Can I do ketamine therapy if I'm in recovery from substance use disorder?
It depends on the substance, your length of sobriety, and the stability of your recovery. Active use of dissociative drugs is an absolute contraindication. For other substances, many programs require a period of stable sobriety (often 6-12 months) and integration with addiction treatment. Some programs specifically offer ketamine as part of comprehensive addiction treatment for conditions like alcohol or cocaine dependence. Honest discussion with your treatment team is essential.
What's the difference between the ketamine my doctor can prescribe and what's used recreationally?
It's the same molecule, but context is everything. Medical ketamine is administered at sub-anesthetic doses (typically 0.5 mg/kg for depression, compared to 1-2 mg/kg for anesthesia) in a controlled setting with medical supervision, informed consent, and integration therapy. Recreational use involves unknown doses, no medical screening, no therapeutic framework, and significant risks including tolerance, bladder damage, and psychological dependence. The therapeutic use of ketamine in psychiatry is evidence-based and increasingly mainstream, but it requires proper medical oversight.
Will my insurance cover ketamine infusion therapy?
For esketamine (Spravato) nasal spray, many commercial insurance plans and Medicare provide coverage with prior authorization, though you'll need to document failed trials of at least two antidepressants. Medicaid coverage varies by state. For off-label IV ketamine infusion, insurance coverage is rare to nonexistent. Most patients pay out of pocket, with costs typically $400-800 per infusion. Some programs offer package pricing for initial series or work with healthcare credit companies.
As a treatment center operator, what's the biggest mistake programs make when adding ketamine services?
Treating ketamine as a standalone intervention rather than integrating it into comprehensive psychiatric care. The infusion is only part of the treatment. Without proper patient selection, integration therapy, coordination with existing providers, and follow-up protocols, outcomes suffer. The second biggest mistake is inadequate attention to regulatory compliance and liability management. Ketamine programs require clinical rigor and operational discipline. Programs that cut corners on either front create risk for patients and the organization.
How long do the effects of ketamine therapy last?
This varies significantly by individual. Some patients experience sustained benefit for weeks or months after an initial series of infusions. Others need maintenance infusions every few weeks to sustain response. The durability of response is significantly improved with integration therapy and concurrent psychiatric care. Ketamine creates a window of opportunity for change, but lasting benefit requires therapeutic work during that window. Most programs recommend an initial series of 6 infusions over 2-3 weeks, then individualized maintenance protocols based on response.
Is Ketamine Infusion Therapy Right for You or Your Program?
Ketamine represents one of the most significant advances in psychiatric treatment in decades, but it's not a universal solution. For patients who've exhausted conventional treatments and meet candidacy criteria, it can be genuinely life-changing. For patients early in their treatment journey or with contraindications, it's not appropriate.
For behavioral health operators, adding ketamine services requires careful evaluation of your patient population, clinical capabilities, regulatory environment, and operational capacity. Done well, it can enhance outcomes for your most complex patients and differentiate your program. Done poorly, it creates clinical and regulatory risk.
Whether you're a patient exploring options or an operator evaluating new service lines, the key is informed decision-making based on clinical evidence, realistic expectations, and proper implementation.
ForwardCare helps behavioral health treatment providers evaluate and implement new clinical service lines with the infrastructure, compliance support, and operational frameworks that ensure quality care. From navigating state licensing requirements to building the clinical systems that support specialized interventions like ketamine therapy, we provide the operational backbone that lets you focus on patient care. Learn how ForwardCare supports innovative behavioral health programs.
